What is Agios?
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the discovery and development of novel medicines targeting cellular metabolism. Headquartered in Cambridge, Massachusetts, the company's primary focus lies in addressing rare diseases through innovative therapeutic approaches. Its lead product, PYRUKYND (mitapivat), is an activator of pyruvate kinase (PK) enzymes, designed for the treatment of hemolytic anemias. Agios is also advancing AG-946, another PK activator aimed at treating lower-risk myelodysplastic syndrome and hemolytic anemias, and AG-181, a stabilizer for phenylalanine hydroxylase for phenylketonuria. The company's pipeline also includes preclinical research into siRNA for polycythemia vera, a rare blood disorder. Founded in 2008, Agios has established a strong foundation in metabolic research to drive its drug development initiatives.
How much funding has Agios raised?
Agios has raised a total of $106M across 1 funding round:
Stock Offering
$106M
Stock Issuance/Offering (2013): $106M, investors not publicly disclosed
What's next for Agios?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Agios Pharmaceuticals. This capital infusion is expected to accelerate the development and commercialization of its promising pipeline, particularly PYRUKYND and its other metabolic disorder therapies. The company's strategic focus on cellular metabolism positions it to address significant unmet medical needs in rare diseases. Future growth will likely involve expanding clinical trials, navigating regulatory pathways, and potentially forging new partnerships to maximize the reach of its innovative treatments. Agios's commitment to scientific rigor and its robust pipeline suggest a strong potential for continued advancement in the biopharmaceutical landscape.
See full Agios company page
